CURI vs PUBM

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 03, 2026

CURI

38.8
AI Score
VS
CURI Wins

PUBM

24.6
AI Score

Investment Advisor Scores

CURI

39score
Recommendation
SELL

PUBM

25score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CURI PUBM Winner
Revenue 38.41M 141.16M PUBM
Net Income 7.55M -13.71M CURI
Net Margin 19.7% -9.7% CURI
Operating Income 7.64M -14.69M CURI
ROE 18.2% -5.7% CURI
ROA 11.2% -2.0% CURI
Total Assets 67.47M 700.04M PUBM
Cash 5.38M 119.97M PUBM
Current Ratio 0.78 1.27 PUBM

Relative Price Performance (Last 90 Days)

CURI 1M: -0.3% · 3M: +3.4% PUBM 1M: +6.0% · 3M: +36.2%

Current Technical Phase

CURI

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (2.8% over 20 days), RSI 53

RSI (14): 52.8 · Price: $2.91

PUBM

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (11.9% over 20 days), RSI 61

RSI (14): 60.8 · Price: $18.42

Fundamentals Snapshot

Metric CURI PUBM
Market Cap — —
Forward P/E 9.4 22.7
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.2% 0.1%
Gross Margin 0.6% 0.6%
Operating Margin 0.4% 0.0%
EPS -0.01 -0.30
Dividend Yield 0.11% —

Frequently Asked Questions

Based on our detailed analysis, CURI is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.